…
Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Daxor Corporation develops and commercializes blood-volume diagnostic systems that quantify total blood volume and red cell mass for use in cardiology, nephrology and hematology. Long-term growth may be supported by increased clinical adoption, improved reimbursement and broader evidence that blood-volume guided care can improve patient management, which could make its niche technology appealing.
Material risks include small commercial scale and liquidity, dependence on a single product, slow clinical uptake and reimbursement uncertainty that could constrain revenue expansion.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 9.17M | 0.54M | 0.28M | 5.18M | 4.75M |
| Net income | 9.17M | 0.54M | 0.28M | 5.18M | 4.75M |
| Selling general administrative | 0.33M | 0.29M | 0.31M | 1.09M | 0.99M |
| Selling and marketing expenses | - | - | 0.63M | - | - |
| Gross profit | 0.19M | 2.13M | 34.41M | 6.31M | 5.82M |
| Ebit | - | 0.62M | -0.18M | -0.86M | -0.75M |
| Ebitda | 9.19M | 2.06M | 0.33M | 5.25M | 4.75M |
| Depreciation and amortization | - | 1.44M | 0.51M | - | - |
| Operating income | 9.19M | 0.62M | 0.33M | 5.25M | 4.75M |
| Other operating expenses | 8.68M | 1.59M | 34.26M | 1.13M | 1.07M |
| Interest expense | 0.02M | 0.09M | 0.05M | 0.07M | 0.02M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Net interest income | -0.02M | -0.09M | -0.05M | -0.07M | -0.02M |
| Income tax expense | - | - | -0.79M | - | - |
| Total revenue | 0.50M | 2.13M | 34.59M | 6.31M | 5.82M |
| Total operating expenses | -9.00M | 1.59M | 0.94M | 1.13M | 1.07M |
| Cost of revenue | 0.31M | - | 0.18M | - | - |
| Total other income expense net | -0.02M | -0.09M | -0.05M | -0.07M | -0.02M |
| Net income from continuing ops | 9.17M | 0.54M | 0.28M | 5.18M | 4.75M |
| Net income applicable to common shares | - | - | - | 5.18M | 4.75M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 46.01M | 36.63M | 34.87M | 30.26M | 24.98M |
| Other current assets | - | 0.01M | -0.01M | - | 0.71M |
| Total liab | 0.12M | 0.84M | 0.86M | 1.29M | 3.83M |
| Total stockholder equity | 45.89M | 35.79M | 34.01M | 28.97M | 21.15M |
| Other current liab | - | - | - | - | -0.09M |
| Common stock | 0.06M | 0.05M | 0.05M | 0.05M | 0.05M |
| Capital stock | 0.06M | 0.05M | 0.05M | 0.05M | 0.05M |
| Retained earnings | 34.80M | 25.63M | 25.09M | 24.79M | 19.61M |
| Other assets | - | 36.63M | 34.87M | 0.02M | 0.73M |
| Total current liabilities | - | 0.11M | 0.10M | 0.06M | 0.09M |
| Net debt | 0.11M | 0.73M | 0.76M | 1.23M | 3.02M |
| Short long term debt total | 0.11M | 0.73M | 0.76M | 1.23M | 3.02M |
| Other stockholder equity | 11.03M | 10.11M | -16.23M | 4.13M | 1.49M |
| Total current assets | - | 0.02M | 0.03M | 0.02M | 0.03M |
| Long term investments | 46.00M | 36.61M | 34.84M | 30.22M | 24.22M |
| Net tangible assets | - | - | - | 28.97M | 21.15M |
| Net receivables | - | 0.01M | 0.01M | 0.02M | 0.03M |
| Accounts payable | 0.11M | 0.11M | 0.10M | 0.06M | 0.09M |
| Accumulated other comprehensive income | 34.80M | - | 25.09M | - | - |
| Non currrent assets other | 0.01M | -36.61M | -34.84M | -30.22M | -24.22M |
| Non current assets total | 46.01M | 36.61M | 34.84M | 30.22M | 24.22M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Change to liabilities | - | - | - | 0.00M | 0.22M |
| Total cashflows from investing activities | 1.18M | 1.94M | 2.75M | - | - |
| Net borrowings | -0.73M | -0.03M | -0.47M | -1.79M | 2.85M |
| Total cash from financing activities | -0.57M | -0.03M | 3.66M | 0.06M | 2.85M |
| Change to operating activities | - | - | - | -0.02M | -0.02M |
| Net income | 9.17M | 0.54M | 0.28M | 5.18M | 4.75M |
| Change in cash | 0.00M | 0.00M | 0.00M | -0.71M | 0.09M |
| Begin period cash flow | 0.00M | 0.00M | 0.00M | 0.71M | 0.62M |
| End period cash flow | 0.00M | 0.00M | 0.00M | 0.00M | 0.71M |
| Total cash from operating activities | -0.60M | 0.03M | -3.66M | -0.77M | -2.76M |
| Issuance of capital stock | - | - | 4.53M | 1.85M | - |
| Change to account receivables | 0.01M | 0.00M | 0.00M | 0.01M | -0.00M |
| Sale purchase of stock | - | - | -0.40M | - | - |
| Other cashflows from financing activities | - | - | -0.40M | 4.08M | 3.71M |
| Change to netincome | - | - | - | -5.94M | -7.72M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.02M | 0.01M | 0.05M | -0.01M | 0.22M |
| Stock based compensation | - | - | 0.63M | - | - |
| Other non cash items | -9.80M | -0.52M | -4.62M | -5.94M | -7.72M |
| Free cash flow | -0.60M | 0.03M | -3.66M | -0.77M | -2.76M |
Sector: Healthcare Industry: Medical Instruments & Supplies
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
|---|---|---|---|---|---|---|---|
| DXR Daxor Corporation |
-0.26 3.11% |
8.10 | 6.01 | 64.52 | 2150.71 | 1.27 | 5.64 |
| ISRG Intuitive Surgical Inc |
-6.82 1.56% |
430.93 | 43.30 | 31.35 | 12.25 | 7.35 | 11.63 |
| ESLOF EssilorLuxottica Société anonyme |
-3.00 1.50% |
197.00 | 44.84 | 27.62 | 4.07 | 2.49 | 3.71 |
| ESLOY Essilor International SA |
-3.05 3.01% |
98.21 | 41.68 | 27.25 | 3.94 | 2.45 | 3.71 |
| BDX Becton Dickinson and Company |
- -% |
215.42 | 31.62 | 13.76 | 2.25 | 2.04 | 2.93 |
Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael Richard Feldschuh | Chairman, Pres & CEO | 1969 |
| Mr. Jonathan Adam Feldschuh | Chief Scientific Officer & Director | 1965 |
| Mr. Robert J. Michel CPA, CPA, M.B.A. | CFO, Chief Compliance Officer & Corp. Sec. | 1957 |
| Ms. Kathryn A. Kornafel | VP of Marketing & Commercial Devel. | NA |
| Mr. Guido Manzo | VP of Sales | NA |
| Ms. Jean Oertel | Sr. VP Commercialization & Customer Experience | NA |
| Mr. Michael Richard Feldschuh | Chairman, President & CEO | 1969 |
| Mr. Robert J. Michel CPA, CPA, M.B.A. | CFO, Chief Compliance Officer & Corporate Secretary | 1957 |
| Ms. Linda Cooper | Vice President of Development & Operations | NA |
| Ms. Kathryn A. Kornafel | Senior VP of Marketing & Commercial Development | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.